Contract Research & Services
Contract Research

reMYND - Alzheimer in vivo CRO News

reMYND - Alzheimer in vivo CRO

Roche presents preclinical efficacy data gathered in collaboration with reMYND's CRO on a promising combo Alzheimer treatment reMYND NV announced today that Bernd Bohrmann (Neuroscience, Roche) is presenting preclinical efficacy data at the leading AD/PD conference held March 6th-10th in Florence, on a novel combination therapy tested in an Alzheimer mouse model in collaboration with reMYND's Contract Research Organization (CRO).
View press release
reMYND’s CRO receives governmental grant for a continued innovation of its offering On its Board Meeting of April 28th 2011, the governmental Agency for Innovation by Science and Technology (IWT) has approved a grant to reMYND’s Contract Research Organization (CRO) for the ‘Evaluation of candidate behavioral and synaptic markers in transgenic Alzheimer mouse models, to assess the feasibility of developing such early onset markers for large scale in vivo testing’, herewith recognizing the deliberated innovation efforts of the CRO.
View press release
reMYND launches a project aimed at improving the predictability of preclinical Alzheimer models as part of the prestigious Marie-Curie International Training Network NPlast reMYND NV announced today its project in NPlast, a prestigious International Training Network funded by the European Commission that is to be launched April 27-28th 2012 at the Leibniz-Institut für Neurobiologie in Magdeburg, Germany.
View press release